The "EVA" trial: Evaluation of the efficacy of diagnostic methods (mammography, ultrasound, MRI) in the secondary and tertiary prevention of familial breast cancer. Preliminary results after the first half of the study period;Die "EVA"-studie: Evaluierung der leistungsfähigkeit diagnostischer verfahren (mammographie, sonographie, MRT) zur sekundären und tertiären prävention des familiären mammakarzinoms - Zwischenergebnisse nach der ersten hälfte der förderungsperiode

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 177, Issue 6, 2005, Pages 818-827

  Kuhl, Christiane K ^a   Schrading, S ^a   Weigel, S ^c   Nussle Kugele K ^b   Sittek, H ^d   Arand, B ^b   Morakkabati, N ^a   Leutner, C ^a   Tombach, B ^c   Nordhoff, D ^c   Rieber, A ^b   Heindel, W ^c   Brambs, H J ^b   Reiser, M ^d   Schild, H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Breast cancer; Early detection; Familial breast cancer; Hereditary breast cancer; Mammography; MRI; Screening; Ultrasound

Indexed keywords

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER INVASION; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FAMILIAL CANCER; FEASIBILITY STUDY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; ULTRASOUND;

EID: 21044447378     PISSN: 14389029     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858203     Document Type: Article

References (40)

1. Lynch HT, Albano WA, Danes BS et al. Genetic predisposition to breast cancer. Cancer 1984; 53: 612-622
2. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56: 265-271
3. Peto J, Collins N, Barfoot R et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999; 91: 943-949
4. Chang-Claude J, Becher H, Hamann U et al. Risikoabschätzung für das familiäre Auftreten von Brustkrebs. Zentralbl Gynäkol 1995; 117: 423-434
5. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71
6. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792
7. Hoskins KF, Stopfer JE, Calzone KA et al. Assessment and counseling for women with a family history of breast cancer: a guide for clinicans. JAMA 1995; 15: 577-585
8. Ford D, Easton DF, Bishop DT et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-695
9. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689
10. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130
11. Marcus JN, Watson P, Page DL et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996; 77: 697-709
12. Armes JE, Egan AJ, Southey MC et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998; 83: 2335-2345
13. Lakhani SR, Jacquemire J, Sloane JP et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90: 1138-1145
14. Robson M, Gilewski T, Haas B et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998; 16: 1642-1649
15. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349: 1505-1510
16. Verhoog LC, Brekelmans CT, Seynaeve C et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351: 316-321
17. Hamann U, Sinn HP. Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res Treat 2000; 59: 185-192
18. Volkers D. Board recommends changes to draft breast cancer screening guidelines. J Natl Cancer Inst 1993; 85: 1794-1796
19. Schmutzler R, Beckmann MW, Kiechle M. Familiäres Mamma- und Ovarialkarzinom. Vorschlag für ein strukturiertes Frü herkennungsprogramm. Dtsch Arztebl 2002; 99: 1372-1378
20. Hartmann LC, Schaid DJ, Woods JE et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. NEJM 1999; 340: 77-84
21. Metcalfe KA, Goel V, Lickley L et al. Prophylactic bilateral mastectomy: patterns of practice. Cancer 2002; 95: 236-242
22. Meijers-Heijboer H, van Geel B, van Putten WL et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-164
23. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers. The PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062
24. Vasen HF, Haites NE, Evans DG et al. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur J Cancer 1998; 34: 1922-1926
25. Kuhl CK, Schmutzler R, Leutner CC et al. Breast MRI screening in 192 high-risk women (proven or suspected carriers of a breast cancer susceptibility gene): preliminary results. Radiology 2000; 215: 267-279
26. Brekelmans CT, Seynaeve C, Bartels CC et al. Rotterdam Committee for Medical and Genetic Counseling. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001; 19: 924-930
27. Kerlikowske K, Grady D, Barclay J et al. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 1993; 270: 2444-2450
28. Kopans DB, Halpern E, Hulka CA. Statistical power in breast cancer screening trials and mortality reduction among women 40-49 with particular emphasis on the National Breast Screening Study of Canada. Cancer 1994; 74: 1196-1203
29. Tilanus-Linthorst M, Verhoog L, Obdeijn IM et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 2002; 102: 91-95
30. Fischer U, Vosshenrich R, Probst A et al. Präoperative MR-Mammographie bei bekanntem Mammakarzinom. Sinnvolle Mehrinformation oder sinnloser Mehraufwand? Fortschr Röntgenstr 1994; 161: 300-306
31. Heywang-Köbrunner SH, Viehweg P, Heinig A et al. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol 1997; 24: 94-108
32. Orel SG, Schnall MD, Powell CM et al. Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology 1995; 196: 115-122
33. Kuhl CK, Sommer T, Gieseke J et al. Fokale und diffuse Läsionen in der dynamischen MR-Mammographie gesunder Probandinnen. Fortschr Röntgenstr 1995; 163: 195-282
34. Kuhl CK, Bieling HB, Gieseke J et al. Premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997; 203: 137-144
35. Stoutjesdijk MJ, Boetes C, Jager GJ et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93: 1095-1102
36. Warner E, Plewes DB, Shumak RS et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001; 19: 3524-3531
37. Podo F, Sardanelli F, Canese R et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 2002; 21: 115-124
38. Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317
39. Kriege M, Brekelmans CT, Boetes C et al. Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-437
40. Surveillance, Epidemiology and End Results (SEER) Program. National Cancer Insitute. SEER Cancer statistics review 1973-1995: female breast cancer: trends in SEER incidence and U.S. mortality. www.seer.ims.nci.nih.gov/ Publications/CSR7395/breast.pdf